Viemed Healthcare, Inc. · NASDAQ:VMD
Viemed Healthcare — Investor Presentation (May 2024)
25 slides from Viemed Healthcare's investor presentation, May 9, 2024
Slide 1: Leading the Healthcare Industry in Home Respiratory Care
Investor Presentation Leading the Healthcare Industry in Home Respiratory Care NASDAQ: VMD May 2024
Slide 2: Disclaimers and Other Important Information
DISCLAIMERS Disclaimers and Other Important Information This presentation (the “Presentation”) about Viemed Healthcare, Inc. (“Viemed” or the “Company”) is dated as May 2024. It is information in a summary form and does not purport to be complete. The data contained herein is derived from various in
Slide 3: Viemed at a Glance
▪ Largest independent specialized provider of non-invasive ventilation (NIV) in the US home respiratory health care industry ▪ Highly profitable with a 25% CAGR in revenue growth since spinout in 2017 ▪ Service offering includes 24x7 in home respiratory care including specialized respiratory therapi
Slide 4: Our Journey
SLEEP MANAGEMENT FOUNDED Annual Revenues: $0.24M USD Respiratory DME specializing in CPAPS & Oxygen HSD Home Sleep Delivered – Specializing in home sleep tests VENTILATOR EXPANSION Non Invasive ventilator introduced to market PHM ACQUISITION Acquired by a public company VIEMED SPIN OUT & LISTING ON
Slide 5: Key Investment Consideration
Key Investment Consideration Market Expansion in Home Medical Equipment (HME) ▪ Sustained growth in HME markets, particularly in complex respiratory and Obstructive Sleep Apnea (OSA) segments ▪ Underserved chronic COPD population qualifying for Non-Invasive Ventilation (NIV) in the home Demographic
Slide 6: Current State of the Industry
Viemed Healthcare, Inc. | Investor Presentation Current State of the Industry The Medicare population is growing DME expenditures are expected to grow at a 5.5% CAGR to $114.5 billion in 2031 5.5% CAGR At the age of 65, patients qualify for Medicare Historical and Projected US DME Expenditures (in $
Slide 7: NIV Market Penetration
NIV Market Penetration 25 Million (estimated) people in the U.S. have COPD 2,500,000 or 10% have stage 4 COPD 1,250,000 or 50% of those with stage 4 COPD develop chronic respiratory failure becoming candidates for our therapy Approximately 80,000 annual Medicare beneficiaries on NIV service * Viemed
Slide 8: Services and Payors
Services and Payors Viemed Healthcare, Inc. | Investor Presentation Ventilation 58% Sleep 14% Oxygen 11% Other 17% Medicare 43% Medicaid/ MCO 7% Medicare Advantage 20% Commercial 17% Other 13% SERVICE MIX 1st Quarter 2024 PAYOR MIX 1st Quarter 2024 Slide 8
Slide 9: The Viemed Solution
The Viemed Solution Registered Respiratory Therapists (RTs) assigned to each patient and on call 24X7 ▪ All RTs are COPD educators ▪ Assess and service medical equipment ▪ Overseen by pulmonologists on staff ▪ Behavioral health specialist support Each patient is given a customized in-home care plan
Slide 10: A Dedicated 24/7 Respiratory Therapist with all our Viemed products
A DEDICATED 24/7 RESPIRATORY THERAPIST with all our Viemed products Ventilators Sleep Therapy Oxygen Therapy Patient Engagement Percussion Vests Slide 10
Slide 11: Proven Organic Growth Strategy
Proven Organic Growth Strategy Location selection ▪ Based on high COPD rates ▪ Target hospitals and facilities with high readmission rates and near existing service area ▪ Leverage existing relationships and operate heavily in rural markets Unique lean deployment model ▪ No costly retail stores ▪ Sa
Slide 12: Complementary Acquisition Initiatives
Complementary Acquisition Initiatives Viemed Healthcare, Inc. | Investor Presentation Strategic Acquisitions ▪ Acquired Home Medical Products, Inc. (HMP) in June 2023 ▪ Immediately accretive to net income and EPS ▪ Contributes to geographic, product, and payor diversity ▪ Revenue synergies complemen
Slide 13: Published Research
Published Research Real-world results Viemed Healthcare, Inc. | Investor Presentation 43% Relative mortality reduction if utilized within 0 - 7 days 11.6% Cost reduction if utilized within 0 – 7 days 7.2% Cost reduction if utilized within 0 – 15 days $5,484 Cost reduction if utilized within 0-7 days
Slide 14: Technology and Remote Care
Technology and Remote Care ▪ Mission of becoming a leading healthcare technology company coupled with high touch human interaction in the home ▪ Goal is to improve quality of life and length of time patients spend with loved ones ▪ Increase efficiency of clinicians through improved remote workflow a
Slide 15: Objectives for the Next Months
Objectives for the Next 24 Months ▪ Grow active patient base while entering new target markets through geographic expansion ▪ Communicate findings from the growing number of research studies to referral sources and payors in order to save more lives and increase market penetration ▪ Diversify payor
Slide 16: Financial Information
, Financial feMed | information Live your Life
Slide 17: Regulatory Update
Regulatory Update ▪ Government reimbursements are stable, with rates indexed to rise with inflation ▪ CMS adoption of 2024 Final Rule increases transparency and accountability for Medicare Advantage plans, improves prior authorization processes ▪ Round 2021 competitive bidding contracts expired on D
Slide 18: Vent Revenue Model
Vent Revenue Model ▪ Monthly rental fee – reimbursed by insurance and covered by Medicare ▪ Uncapped rental contract for ventilators (58% of 1Q24 revenue) ▪ Average monthly vent reimbursement of $1,050 ▪ Pricing includes equipment rental, RT service, supplies and maintenance of equipment ▪ Other maj
Slide 19: Historical Financial Performance
5,500 6,000 6,500 7,000 7,500 8,000 8,500 9,000 9,500 10,000 10,500 Viemed Healthcare, Inc. | Investor Presentation Historical Financial Performance Active Vent Rental Patients 10,450 as of 3/31/24 $140,000,000 $120,000,000 $110,000,000 $100,000,000 $80,000,000 $60,000,000 $40,000,000 $20,000,000 $0
Slide 20: Capital Markets Profile
Capital Markets Profile Viemed Healthcare, Inc. | Investor Presentation 38,816,766 & 40,680,277 Shares outstanding & fully diluted $7.3M 20% Insider beneficial ownership Cash on hand in USD Total LT debt in USD $6M Total staff 1,095 Market cap as of April 30, 2024: $320M (USD) Stock price as of Apri
Slide 21: Board of Directors
Board of Directors Viemed Healthcare, Inc. | Investor Presentation Casey Hoyt Chief Executive Officer and Director Randy Dobbs Chairman of the Board and Independent Director Todd Zehnder Chief Operating Officer and Director Nitin Kaushal Independent Director Bruce Greenstein Independent Director Tim
Slide 22: Corporate Structure
Viemed Healthcare, Inc. | Investor Presentation Corporate Structure Viemed Healthcare Inc. (Canadian Parent Company Listed on NASDAQ) Viemed Inc. (Delaware Corporation/US Subsidiary) Home Sleep Delivered, LLC (US Sub- Louisiana) Viemed Clinical Services, LLC (US Sub- Louisiana) Viemed Healthcare Sta
Slide 23: Investor Relations Contact
Investor Relations: Glen Akselrod Bristol Capital IR glen@bristolir.com Tel: 905 326 1888 Slide 23
Slide 24: Appendix
VieMed | Appendix Live your Life
Slide 25: Reconciliation of Adjusted EBITDA
Viemed Healthcare, Inc. | Investor Presentation 2020 2021 2022 2023 1Q 2024 YTD Reconciliation of Adjusted EBITDA(1) Net Income 31.5$ 9.1$ 6.2$ 10.2$ 1.6$ Depreciation & Amortization 9.6 11.3 15.6 21.9 6.3 Interest Expense (income) 0.5 0.3 0.2 0.4 0.2 Transaction Costs - - - 0.5 0.1 Stock-based Comp